Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Quantum BioPharma (NASDAQQNTM) announced the successful completion of its Phase 1 clinical trial evaluating Lucid-21-302 (“Lucid-MS”), a first-in-class neuroprotective compound for multiple sclerosis. A final safety review committee meeting confirmed that Lucid-MS was well-tolerated with no serious adverse events. The drug, designed to stabilize the myelin sheath and protect against demyelination, showed promising safety results, paving the way for a Phase 2 trial in MS patients. Company executives emphasized the milestone as a key step toward drug approval and commercialization.

Safety Review Committee Found No Safety Concerns Following Milestone Trial

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (“BTC”) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $2,000,000. As previously announced, the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

Quantum BioPharma (NASDAQQNTM) has retained MZHCI, an MZ Group company, to lead its investor relations and financial communications efforts. The initiative aims to enhance the company’s visibility within the investment community, emphasizing its portfolio focused on brain disorders and alcohol health. MZ will highlight Quantum BioPharma’s products, including unbuzzd and rekvry, which address excessive alcohol use, and its research into demyelinating diseases such as multiple sclerosis. Chris Tyson, executive vice president at MZ North America, noted the significant market potential for these innovations.

TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“MZ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.

Quantum BioPharma (NASDAQQNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry , an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials.

TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of Enterprise Canada Inc. (“Enterprise”) and Empire Market Ventures, LLC (“Empire”) (together, the “Agencies”) to lead its comprehensive public relations and investor awareness programs, respectively, across all key markets.

The company has attracted heavy attention after its dietary supplement, Unbuzzd, showed that it can reduce blood alcohol concentration rapidly in a clinical trial.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.

Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Wondering what's happening in Thursday's pre-market session? Find an overview in this article.

Quantum BioPharma shares are surging Thursday after its licensee, Celly Nutrition, engaged a New York investment bank to raise up to $10 million and explore a potential U.S. initial public offering.

Quantum BioPharma (NASDAQQNTM) announced that its licensee, Celly Nutrition Corp., has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering on a major U.S. exchange. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives a 7% royalty on sales of its product, unbuzzd, until payments total $250 million, after which royalties drop to 3% in perpetuity. Celly Nutrition signed a Letter of Engagement on Feb. 4, 2025, for advisory services related to a potential uplisting, reverse merger, or IPO. CEO John Duffy emphasized the capital raise will support marketing and distribution expansion for unbuzzd, while Board Co-Chair Gerry David highlighted strong investor interest in the brand.

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to $10 million USD in capital and explore an initial public offering on a major US public exchange, subject to requisite regulatory approval.

Discover the stocks with unexpected trading volume in today's session on the US markets.

The company said it also led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Let's have a look at the gap up and gap down stocks in today's session.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Shares of Quantum BioPharma Ltd. (NASDAQQNTM) are soaring more than 70% on Tuesday after the company announced positive clinical trial results for its dietary supplement, unbuzzd, which accelerates the reduction of blood alcohol concentration.